JPMorgan raises target for Regeneron stock to USD 950.00

Published on 10/07/2026 at 15:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 16.70 percent to USD 4.29 billion. Regeneron stock costs EUR 658.95 versus EUR 656.05 on October 7, 2026.

Aquarellmalerei eines modernen Forschungscampus mit Glastürmen am Flussufer — Regeneron Pharma US75886F1075 präsentiert eine stimmungsvolle Aquarell-Ansicht eines modernen Forschungscampus entlang eines ruhigen Flussufers, Illustration mit AI erstellt.

JPMorgan raised its target for Regeneron stock from USD 900.00 to USD 950.00 in a note dated October 6, 2026, while maintaining an overweight rating, as MarketBeat reports. At Lang & Schwarz, the stock was trading at EUR 658.95 on October 7, 2026 at 3:17 p.m. CEST, up 0.44 percent versus the prior close of EUR 656.05.

Cancer pipeline reaches ESMO

Regeneron announced on October 6, 2026, that it will present 10 abstracts at the European Society for Medical Oncology Congress, which runs from October 23 to October 27 in Madrid. The program includes late-breaking Phase 3 C-POST survival data for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma, according to Regeneron.

The same release lists final Phase 2 data for neoadjuvant Libtayo and research on Factor XI antibodies for cancer-associated thrombosis. Regeneron states that the potential uses of several candidates remain investigational, making the ESMO presentations a pipeline milestone rather than a new approval.

Results provide the earnings base

For the second quarter of 2026, Regeneron reported USD 4.29 billion in revenue, up 16.70 percent from the same period a year earlier, while adjusted earnings per share reached USD 14.29 versus a USD 10.16 consensus estimate, according to MarketBeat. The revenue comparison gives the oncology pipeline a stronger financial backdrop than a development update alone.

JPMorgan's USD 950.00 target sits above the USD 738.72 primary-exchange quote reported for October 6, 2026, while the Nasdaq 52-week range extends from USD 541.00 to USD 859.34. The gap between the target and the latest primary-exchange quote reflects an analyst view, not a guaranteed outcome.

October 30 sets the next test

Regeneron will report third-quarter 2026 financial and operating results before the U.S. financial markets open on October 30, 2026, with a conference call scheduled for 8:30 a.m. ET, according to Regeneron. That report will show whether the second-quarter revenue growth and earnings outperformance carried into the next period.

Regeneron stock was trading at EUR 658.95 at Lang & Schwarz on October 7, 2026 at 3:17 p.m. CEST, plus 0.44 percent versus the Lang & Schwarz prior close of EUR 656.05. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.